Protobios (PB) is an Estonian biotechnology company founded in October 2003, and is positioning itself as a developer of new diagnostic tests and also as a service provider in the field of immunome analysis Discovering potential of immunoprofiling A drop of human blood is presumed to have 10 powered 11 specific antibodies that recognize different immunogens (natural antigen epitopes and antigenic mimics, mimotopes). Although the potential size of the human immunoglobulin repertoire has been estimated, the understanding of its overall involvement in the immune response has remained elusive, mainly because we are not yet able to decipher it. Protobios' novel immunoprofiling technology MVA (Mimotope Variation Analysis) has overcome that problem. MVA technology enables to obtain quantitative and qualitative antibody binding profiles (immunoprofiles). A binding profile can be made to describe a single molecule up to individuals or populations. An immunoprofile describes the state of the immune system and its ability to protect the body. That is considered an innovative tool interpreting health related data for diseases; health conditions and propels the caregivers towards a new level of understanding regarding the prevention and treatment. Alternatively allows MVA to offer reliable services such as epitope mapping, antibody analyses, immunogenicity assessment etc. to biotechnology industry. MVA technology is based on screening of combinatorial peptide display library, next generation DNA sequencing and proprietary bioinformatics analysis. Learn more about MVA, its applications on www.protobios.com